Table 1: RSV illness in children less than 2 years of age with comparisons among high risk groups admitted post-2014 guidance.
| Not Eligible for Palivizumab in 2012 or 2014 (n = 509) N(%) or Median (IQR) |
Eligible per 2012; Excluded per 2014 (n = 16) N(%) or Median (IQR) |
Eligible per 2014
(n = 18) N(%) or Median (IQR) |
P-value | |
|---|---|---|---|---|
| Sex (% male) | 56% (283) | 25% (4) | 50% (9) | 0.253 |
| Previously healthy | 86% (439) | 62.5% (10) | 5% (1) | 0.001 |
| Receipt of palivizumab | < 1% (2) | 6% (1) | 56% (10) | 0.007 |
| Premature (< 37 weeks) | 16% (82) | 87.5% (14) | 67% (12) | 0.306 |
| Age in months | 3.24 (IQR 1.44-7.92) | 3.48 (IQR 1.62-6.27) | 11.04 (IQR 6.72-15.15) | 0.006 |
| CLD | < 1% (3) | 6% (1) | 50% (9) | 0.016 |
| CHD | 0% (0) | 6% (1) | 33% (6) | 0.127 |
| Length of stay | 2 (IQR 1-4) | 4 (IQR 2-9.25) | 4 (IQR 1.25-6) | 0.510 |
| ICU or IMC admission | 30% (154) | 62.5% (10) | 56% (10) | 0.951 |
| Oxygen requirement > 2 L | 44% (223) | 62.5% (10) | 61% (11) | 1.000 |
| Mechanical ventilation | 47% (2) | 25% (4) | 6% (1) | 0.260 |
| Bacterial pneumonia | 10% (49) | 19% (3) | 6% (1) | 0.510 |